Rohit Bakshi

Q: What Schools Are Affiliated With Rohit Bakshi

Rohit Bakshi is affiliated with the following schools: University at Buffalo, Cornell University, Harvard University

Rohit Bakshi's AcademicInfluence.com Rankings

Rohit Bakshi

Computer Science

#8812

World Rank

#9264

Historical Rank

Computational Linguistics

#2030

World Rank

#2052

Historical Rank

Machine Learning

#3710

World Rank

#3756

Historical Rank

Artificial Intelligence

#4025

World Rank

#4083

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Rohit Bakshi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rohit Bakshi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change (2005) (537)
Quality of life in patients with multiple sclerosis The impact of fatigue and depression (2002) (483)
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability (2000) (466)
Fatigue associated with multiple sclerosis: diagnosis, impact and management (2003) (428)
The measurement and clinical relevance of brain atrophy in multiple sclerosis (2006) (426)
Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. (2004) (382)
MRI in multiple sclerosis: current status and future prospects (2008) (342)
Gray matter involvement in multiple sclerosis (2007) (341)
Acute disseminated encephalomyelitis in children. (2002) (340)
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation (2014) (336)
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis (2006) (281)
Iron in chronic brain disorders: Imaging and neurotherapeutic implications (2007) (269)
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis (2010) (249)
T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. (2002) (230)
Smoking and disease progression in multiple sclerosis. (2009) (217)
Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. (2008) (200)
Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. (2001) (199)
Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis (2004) (192)
Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients (1999) (191)
The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction (2005) (178)
Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method (2004) (177)
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). (2006) (174)
Magnetic Resonance Imaging of Iron Deposition in Neurological Disorders (2006) (172)
Nonrandomized Comparison of Local Urokinase Thrombolysis Versus Systemic Heparin Anticoagulation for Superior Sagittal Sinus Thrombosis (2001) (168)
Brain CT and MRI Findings in 100 Consecutive Patients with Intracranial Tuberculoma (2003) (154)
Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. (2002) (152)
Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. (2000) (140)
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event (2006) (139)
Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks (2018) (135)
MRI findings in Susac’s syndrome (2003) (133)
Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. (2002) (129)
Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis (2009) (126)
A semiautomated measure of whole-brain atrophy in multiple sclerosis (2003) (125)
Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis (2007) (117)
T1‐ and T2‐Based MRI Measures of Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis (2007) (117)
Exploration of machine learning techniques in predicting multiple sclerosis disease course (2017) (117)
The association between cognitive impairment and quality of life in patients with early multiple sclerosis (2010) (116)
Significance of hyperintense vessels on FLAIR MRI in acute stroke (2000) (115)
Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study (2003) (115)
Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis (2011) (114)
Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients (2001) (114)
Intraventricular CSF pulsation artifact on fast fluid-attenuated inversion-recovery MR images: analysis of 100 consecutive normal studies. (2000) (114)
Regional lobar atrophy predicts memory impairment in multiple sclerosis. (2005) (108)
Fluid-attenuated inversion-recovery MR imaging in acute and subacute cerebral intraventricular hemorrhage. (1999) (103)
Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis (2005) (103)
Fatigue as a window to the brain (2006) (100)
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis (2018) (98)
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. (2005) (98)
Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis (2004) (91)
Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging Study (2003) (90)
Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis (1990) (86)
Lymphomatosis cerebri Presenting as a Rapidly Progressive Dementia: Clinical, Neuroimaging and Pathologic Findings (1999) (85)
Role of MRI in multiple sclerosis I: inflammation and lesions. (2004) (85)
Regional Brain Atrophy Is Associated With Physical Disability in Multiple Sclerosis: Semiquantitative Magnetic Resonance Imaging and Relationship to Clinical Findings (2001) (85)
Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study (2009) (84)
The Relationships among MRI‐Defined Spinal Cord Involvement, Brain Involvement, and Disability in Multiple Sclerosis (2012) (84)
Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis (2017) (83)
Fluoxetine and restless legs syndrome (1996) (81)
MRI in multiple sclerosis: What’s inside the toolbox? (2007) (81)
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis (2006) (80)
Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis (2002) (80)
The Relationship between Normal Cerebral Perfusion Patterns and White Matter Lesion Distribution in 1,249 Patients with Multiple Sclerosis (2012) (78)
3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis (2009) (78)
Identification and Clinical Impact of Multiple Sclerosis Cortical Lesions as Assessed by Routine 3T MR Imaging (2011) (78)
Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis (1998) (78)
Magnetic Resonance Imaging in Multiple Sclerosis. (2018) (76)
Acute hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings (2003) (74)
Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. (2004) (72)
COVID-19 mRNA vaccination leading to CNS inflammation: a case series (2021) (72)
Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. (2004) (71)
MRI findings in lumbar puncture headache syndrome: abnormal dural-meningeal and dural venous sinus enhancement. (1999) (71)
Imaging of multiple sclerosis: Role in neurotherapeutics (2005) (70)
Spatial distribution of multiple sclerosis lesions in the cervical spinal cord (2019) (68)
Normal Findings on Brain Fluid-Attenuated Inversion Recovery MR Images at 3T (2009) (68)
The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis (2012) (67)
MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images (1998) (66)
Cranial Magnetic Resonance Imaging Findings in Bacterial Endocarditis: The Neuroimaging Spectrum of Septic Brain Embolization Demonstrated in Twelve Patients (1999) (66)
Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review (2017) (64)
Extra temporal involvement in herpes simplex encephalitis (2005) (63)
Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis (2010) (63)
Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences (2003) (59)
Gut Microbiome in Progressive Multiple Sclerosis (2021) (59)
Role of Fluid-Attenuated Inversion Recovery in the Diagnosis of Meningitis: Comparison with Contrast-Enhanced Magnetic Resonance Imaging (2004) (58)
Construct validity and frequency of euphoria sclerotica in multiple sclerosis. (2004) (58)
The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis (2019) (57)
Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis (2012) (57)
Dizziness and yield of emergency head CT scan: Is it cost effective? (2005) (57)
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. (2008) (56)
MR imaging in toxoplasmosis encephalitis after bone marrow transplantation: paucity of enhancement despite fulminant disease. (2004) (56)
T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis (2009) (56)
MRI in multiple sclerosis: a review of the current literature. (2012) (54)
A 3T MR Imaging Investigation of the Topography of Whole Spinal Cord Atrophy in Multiple Sclerosis (2011) (54)
Magnetic resonance imaging findings in acute cerebellitis. (1998) (53)
Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity (2017) (52)
COVID-19 in teriflunomide-treated patients with multiple sclerosis (2020) (51)
Neuroimaging of Stroke: A Review (2003) (51)
N-methyl-d-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: behavioral and histological studies (1992) (49)
Diffusion-weighted MRI as an evolving standard of care in acute stroke (2000) (49)
Syncope and head CT scans in the emergency department (2005) (46)
Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (2015) (45)
Rate of brain atrophy in benign vs early multiple sclerosis. (2009) (45)
Multiple Sclerosis Lesion Segmentation with Tiramisu and 2.5D Stacked Slices (2019) (44)
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis (2004) (44)
Interhemispheric asymmetry of brain diffusivity in normal individuals: a diffusion-weighted MR imaging study. (2005) (43)
Blockade of the glycine modulatory site of NMDA receptors modifies dynorphin-induced behavioral effects (1990) (42)
Short-term brain atrophy changes in relapsing–remitting multiple sclerosis (2004) (42)
Imaging outcome measures of neuroprotection and repair in MS (2019) (40)
Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis (2008) (38)
Hemodynamic changes in simple partial epilepsy: A functional MRI study (2000) (38)
Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. (2007) (38)
7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions (2019) (37)
Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients (2008) (37)
Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis (2008) (35)
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS (2017) (33)
Lifespan normative data on rates of brain volume changes (2019) (33)
Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis (2017) (33)
Incorporating Domain Knowledge Into the Fuzzy Connectedness Framework: Application to Brain Lesion Volume Estimation in Multiple Sclerosis (2007) (32)
Microstructural Changes in the Striatum and Their Impact on Motor and Neuropsychological Performance in Patients with Multiple Sclerosis (2014) (32)
Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis (2016) (32)
Dual‐Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI (2017) (31)
Power estimation for non-standardized multisite studies (2016) (31)
MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis (2014) (30)
MRI in cerebral intraventricular hemorrhage: analysis of 50 consecutive cases (1999) (29)
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study (2009) (28)
Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1‐weighted brain MRI acquisitions (2018) (28)
Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. (2020) (27)
Automatic spinal cord localization, robust to MRI contrasts using global curve optimization (2018) (27)
Intensity warping for multisite MRI harmonization (2019) (27)
A Magnetization Transfer MRI Study of Deep Gray Matter Involvement in Multiple Sclerosis (2006) (27)
MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis (2009) (26)
Neuroimaging of HIV and AIDS related illnesses: a review. (2004) (25)
Corpus Callosum Atrophy Correlates with Gray Matter Atrophy in Patients with Multiple Sclerosis (2015) (25)
T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis (2015) (24)
An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions (2017) (24)
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis (2020) (24)
Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models (2015) (24)
Spike and-Slab Group LASSOs for Grouped Regression and Sparse Generalized Additive Models (2019) (23)
Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors (2014) (23)
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2 (2014) (22)
Superior sagittal sinus thrombosis secondary to hyperthyroidism. (2000) (22)
Multiple Sclerosis: Immunology, Pathology, and Pathophysiology (2004) (22)
Multiple Sclerosis Medical Image Analysis and Information Management (2005) (22)
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis (2016) (21)
Magnetic Resonance Imaging Advances in Multiple Sclerosis (2005) (21)
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing–remitting multiple sclerosis (2009) (21)
Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability (2017) (21)
Multisite reliability and repeatability of an advanced brain MRI protocol (2019) (21)
Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. (2019) (21)
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis (2015) (21)
Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. (2010) (21)
Detection of aryl hydrocarbon receptor agonists in human samples (2018) (20)
Cerebral ventricular empyema associated with severe adult pyogenic meningitis: computed tomography findings (1997) (20)
Neurosarcoidosis presenting as a large suprasellar mass. Magnetic resonance imaging findings. (1998) (19)
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis (2011) (19)
Diffusion‐Weighted Magnetic Resonance Imaging in Superior Sagittal Sinus Thrombosis (2002) (19)
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis (2017) (18)
The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis (2016) (18)
Neuroimaging Curriculum for Neurology Trainees: Report from the Neuroimaging Section of the AAN (2003) (18)
Acute demyelinating optic neuritis: a review. (2008) (17)
Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis (2018) (17)
Guillain-Barré syndrome after combined tetanus-diphtheria toxoid vaccination (1997) (17)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. (2019) (17)
Is fluid-attenuated inversion recovery MRI more sensitive than conventional MRI for hypoglycemic brain injury? (2000) (16)
Local thrombolytic treatment of cerebral venous thrombosis in three paediatric patients. (2006) (16)
The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. (2017) (16)
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial (2017) (16)
Neuroimaging of toxic and metabolic disorders. (2008) (16)
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study (2020) (16)
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study (2012) (15)
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis (2016) (15)
Combination Therapy for Multiple Sclerosis (2004) (15)
MRI detection of hypointense brain lesions in patients with multiple sclerosis: T1 spin-echo vs. gradient-echo. (2015) (15)
Correlation between white matter damage and gray matter lesions in multiple sclerosis patients (2017) (15)
18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis (2018) (14)
Special populations: The management of seizures in HIV-positive patients (2004) (14)
MRI phenotypes in MS (2019) (14)
Effects of Systolic Blood Pressure on Brain Integrity in Multiple Sclerosis (2018) (14)
Functional imaging during covert auditory attention in multiple sclerosis (2004) (14)
New Error type and Recall Consistency Indices for the Brief Visuospatial Memory Test – Revised: Performance in Healthy Adults and Multiple Sclerosis Patients (2008) (13)
7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. (2020) (13)
Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis (2018) (13)
The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis (2018) (13)
Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines (2018) (12)
Superior sagittal sinus thrombosis due to lithium: Local urokinase thrombolysis treatment (2000) (12)
Regional White Matter Atrophy−Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data (2009) (11)
Diffuse Magnetic Resonance Imaging White-Matter Changes in a 15-Year-Old Boy With Mitochondrial Encephalomyopathy (2002) (11)
The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis (2015) (11)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis (2019) (11)
A dual modeling approach to automatic segmentation of cerebral T2 hyperintensities and T1 black holes in multiple sclerosis (2018) (10)
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis (2017) (10)
Gray matter microglial activation in relapsing vs progressive MS (2019) (10)
Primary central nervous system lymphoma masquerading as herpes encephalitis: clinical, magnetic resonance imaging, and pathologic findings. (2002) (10)
The NAIMS cooperative pilot project: Design, implementation and future directions (2018) (10)
Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study (2020) (10)
TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis (2017) (9)
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability (2021) (9)
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis (2017) (9)
Thoracic myelopathy complicating acute meningococcal meningitis: MRI findings. (2002) (9)
The cerebral intravascular enhancement sign is not specific: a contrast-enhanced MRI study (1999) (9)
Vascular compression in trigeminal neuralgia shown by magnetic resonance imaging and magnetic resonance angiography image registration. (2001) (8)
Robust Multiple Sclerosis Lesion Inpainting with Edge Prior (2020) (8)
An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis (2016) (8)
MRI activity in MS and completed pregnancy (2020) (7)
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis (2016) (7)
Acute middle cerebral artery thrombosis demonstrated by cranial computed tomography: the "dense MCA" sign. (1998) (7)
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis (2011) (7)
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis (2022) (7)
Diffuse dural gadolinium MRI enhancement associated with bilateral chronic subdural hematomas. (2004) (7)
Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis (2020) (7)
Aggressive Giant Pituitary Adenoma Presenting as a Nasopharyngeal Mass: Magnetic Resonance Imaging and Pathologic Findings (2004) (7)
Regional microglial activation in the substantia nigra is linked with fatigue in MS (2020) (6)
Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment (2003) (6)
Use of Imaging in Multiple Sclerosis (2010) (6)
Optimized double inversion recovery for reduction of T1 weighting in fluid‐attenuated inversion recovery (2012) (6)
Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis (2015) (6)
Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. (2017) (5)
MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis (2021) (5)
Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis (2021) (5)
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes (2022) (5)
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease (2021) (5)
Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis. (2022) (5)
TAPAS: A Thresholding Approach for Probability Map Automatic Segmentation in Multiple Sclerosis (2019) (4)
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. (2020) (4)
Serum antibodies to phosphatidylcholine in MS (2020) (4)
Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS (2022) (4)
Magnetic resonance imaging in multiple sclerosis. (2005) (4)
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study (2022) (3)
Neuroimaging: Anything to do with neurotherapeutics? (2005) (3)
Detection of Cortical and Deep Gray Matter Lesions in Multiple Sclerosis Using DIR and FLAIR at 3T (2020) (3)
Cortical Thickness Measurements from 1.5T vs. 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (P4.179) (2016) (3)
B4GALT6 regulates astrocyte activation during CNS inflammation (INM8P.360) (2015) (3)
Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis (2018) (3)
MRI and Multiple Sclerosis: What Happened in the Last 10 Years? (2007) (3)
Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease (2016) (3)
[F-18]PBR06 PET to assess TSPO binding and its association with brain atrophy and disability in multiple sclerosis (P3.386) (2018) (3)
The New Era of Multiple Sclerosis Therapeutics (2012) (2)
Lesion network localization of depression in multiple sclerosis (2023) (2)
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010 (2010) (2)
Association between low testosterone and brain atrophy in men multiple sclerosis. (S38.006) (2015) (2)
OptiC: Robust and Automatic Spinal Cord Localization on a Large Variety of MRI Data Using a Distance Transform Based Global Optimization (2017) (2)
MIMoSA: An Approach to Automatically Segment T2 Hyperintense and T1 Hypointense Lesions in Multiple Sclerosis (2018) (2)
Neuroimaging: Anything to do with neurotherapeutics? (2005) (2)
Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis (2022) (2)
Biochemical Changes and Secondary Tissue Injury After Brain and Spinal Cord Ischemia (1992) (2)
MRI findings in Susac's syndrome. Author's reply (2004) (2)
Advances in neuroimaging technology: state of the art. (2007) (2)
Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective (2011) (2)
Deep Gray Matter Segmentation from 1.5T vs. 3T MRI in Normal Controls and Patients with Multiple Sclerosis (P4.171) (2016) (2)
The new Editor‐in‐Chief of the Journal of Neuroimaging: Rohit Bakshi (2015) (2)
Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis (2009) (2)
Abstract #7: Voxel Based Morphometry with DARTEL in Multiple Sclerosis (2010) (1)
Cerebral leptomeningeal enhancement is common and associated with cortical and thalamic lesions in relapsing-remitting multiple sclerosis: A 7T MRI study (S31.002) (2019) (1)
Detection of Metals in Multiple Sclerosis Brain Tissue using Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray (EDX) Analyses (2004) (1)
Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset (2022) (1)
The Contribution of Cortical Lesions to a Magnetic Resonance Disease Severity Scale in Multiple Sclerosis (P4.168) (2016) (1)
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis (2010) (1)
Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. (2023) (1)
T1 Black Holes and Gray Matter Damage (2007) (1)
Increasing Efficiency of Intracranial Cavity Determination from High-Resolution 3 Tesla(T) MRI Scans of the Brain (P06.121) (2013) (1)
Update in Neuroimaging (2011) (1)
Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008 (2008) (1)
Whole Brain Volume Measured from 1.5T vs. 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (P6.156) (2015) (1)
The Role of the Spinal Cord as an Adjunct to the Brain in the MRI Definition of “No Evidence of Disease Activity” in Multiple Sclerosis (P4.169) (2016) (1)
Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study (2020) (1)
Atrophy of the Brain and Spinal Cord in Multiple Sclerosis (2004) (1)
Sensory Abnormalities in MS (2004) (1)
Imaging of multiple sclerosis: Role in neurotherapeutics (2005) (0)
Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases (2021) (0)
A longitudinal study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. (P6.170) (2015) (0)
Large-scale normative volumes of brain structures as assessed by SIENAX (2018) (0)
Younger age at multiple sclerosis onset is associated with worse outcomes at age 50 (2022) (0)
Normative rates of healthy age-related brain volume changes as assessed by SIENA on a large MRI dataset (2017) (0)
Prolonged Marijuana-like Dysphoria After Subcutaneous Sumatriptan (1996) (0)
ORIGINAL RESEARCH Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis (2008) (0)
ORIGINAL RESEARCH Regional White Matter AtrophyBased Classification of Multiple Sclerosis in Cross- Sectional and Longitudinal Data (2009) (0)
Neuroimaging essentials for the clinician. (2008) (0)
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study (2010) (0)
Neuroimaging: What a great ride! (2007) (0)
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine (2023) (0)
Optimization of GSH Measurement in Multiple Sclerosis (2012) (0)
Validation of Routine High-Resolution 3T MRI Morphometry in Multiple Sclerosis (P6.164) (2015) (0)
Evaluation of the revised 2013 MS clinical course definitions in the CLIMB real world cohort (P5.190) (2015) (0)
Sample Size Requirements for Treatment Effects Using Deep Gray Matter Volume from 3T MRI in Progressive Forms of Multiple Sclerosis (P4.173) (2016) (0)
TMS targets for multiple sclerosis related depression derived using a precomputed functional connectome (2023) (0)
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model (2010) (0)
Title: Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks Authors: (2018) (0)
Cerebral White and Grey Matter MRI Segmentation with Lesion In-Painting in Multiple Sclerosis (2010) (0)
Improved Specificity of Multiple Sclerosis Lesion Segmentation from Dual-Sensitivity MRI Morphometry (P6.116) (2015) (0)
New insights through pictures neuroimaging highlights (2003) (0)
An MRI-Defined Measure of Cerebral Lesion Severity to Assess the Therapeutic Effect of Glatiramer Acetate in Multiple Sclerosis (P4.172) (2016) (0)
Pre-filling MS lesions on T1 and T2-weighted images for improved tissue segmentation. (2010) (0)
Site-directed mutagenesis studies of h 15-LOX-1 and their effects on inhibitor potency (2015) (0)
MRI Characteristics of Malignant Multiple Sclerosis (S50.001) (2012) (0)
Is Baseline MRI Predictive of Response to Fingolimod Treatment in Multiple Sclerosis? (P3.280) (2015) (0)
A New Composite Scale Of MRI-Defined Disease Severity In Multiple Sclerosis (P6.118) (2014) (0)
Letter to the Editor (2000) (0)
Diagnostic yield of head computed tomography scanning in the evaluation of 112 consecutive patients with dizziness (1999) (0)
Solitary inflammatory demyelination in the brain or spinal cord with tumor-like MRI presentations. (2001) (0)
Neuroimaging News and Tips (2008) (0)
Therapeutic Advances in Neurological Disorders (2015) (0)
Neuroimaging advances. Highlights from the 32nd Annual Meeting of the American Society of Neuroimaging, January 22-25, 2009, Orlando, FL. (2009) (0)
Serum microRNAs Are Related to Brain MRI Lesions and Atrophy in Patients with Multiple Sclerosis (P4.140) (2016) (0)
A Gender-Based 3T MRI Comparison Of Brain And Spinal Cord Involvement In Relapsing-Remitting Multiple Sclerosis (S13.001) (2014) (0)
Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis (2022) (0)
Microglial Activation in the Deep Grey Matter is Associated with Regional Atrophy and Physical Disability in Multiple Sclerosis (S12.003) (2019) (0)
A local group differences test for subject-level multivariate density neuroimaging outcomes. (2019) (0)
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis (2008) (0)
Inter-scanner brain MRI volumetric biases persist even in a harmonized multi-subject study of multiple sclerosis (2022) (0)
DTI Evidence of Microstructural Damage to the Striatum in Subjects with Multiple Sclerosis (P06.107) (2013) (0)
Poster Abstract #15: MRI Measurement of Whole Spinal Cord Volume at 3T: Reproducibility and Relevance to Multiple Sclerosis (2008) (0)
Brain Iron Deposition in Multiple Sclerosis (2009) (0)
The New Era of Multiple Sclerosis Therapeutics (2012) (0)
The Longitudinal Relationship between Cognitive Dysfunction and Global vs. Regional Brain Atrophy in Relapsing Remitting Multiple Sclerosis: A One Year Follow-Up Study (S51.004) (2012) (0)
Multiple Sclerosis: Hyperintense LesionsintheBrainonNonenhanced T1-weightedMRImagesEvidencedas (2007) (0)
Diffusion Tensor MRI and Cognition in Leukoaraiosis (2004) (0)
Neurotherapeutics to publish primary research papers (2010) (0)
REPLY (1998) (0)
Glioblastomas in New England ophthalmologists. (1991) (0)
Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report (2023) (0)
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients (2022) (0)
Ginkgo leaf sign on X-ray chest due to subcutaneous emphysema in a COVID-19 patient (2021) (0)
Segmentation of Multiple Sclerosis Lesions across Hospitals: Learn Continually or Train from Scratch? (2022) (0)
Chapter 6. Use of Imaging in Multiple Sclerosis (2008) (0)
Quantification of Global Cerebral Gray Matter Atrophy in Multiple Sclerosis from 3T MRI (P03.056) (2012) (0)
Brain and Spinal Cord MRI Findings in Primary Progressive vs. Relapsing-Remitting Multiple Sclerosis (P4.170) (2016) (0)
Substantia Nigra Pathology Predicts Disability in Multiple Sclerosis (2010) (0)
Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study (P2.371) (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rohit Bakshi?

Rohit Bakshi is affiliated with the following schools:

Rohit Bakshi's Academic­Influence.com Rankings

Why Is Rohit Bakshi Influential?

Rohit Bakshi's Published Works

Published Works

What Schools Are Affiliated With Rohit Bakshi?

Rohit Bakshi's AcademicInfluence.com Rankings